Navigation Links
Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
Date:2/9/2009

- First time IV formulation of clopidogrel, the active ingredient in

PLAVIX(R), is studied in humans -

KING OF PRUSSIA, Pa., Feb. 9 /PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate (the active ingredient in PLAVIX(R)), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 29-31, 2009. The poster will be presented at the ACC's Innovation in Intervention: i2 Summit 2009 in partnership with Cardiovascular Research Foundation.

    Presentation Number: 2515-749

    Abstract Title:     Assessment of the pharmacokinetic and pharmacodynamic
                        effects of intravenous clopidogrel in humans

    Time:               Monday, Mar 30, 2009, 9:30 AM -10:30 AM

    Topic:              Pharmacotherapy - Interventional Aspects

    Authors:            Daniel Cushing, Raymond Lipicky, Peter Kowey,
                        Christopher Cannon, Michael Adams, Warren Cooper,
                        Gerold Mosher, Prism Pharmaceuticals

"We are very pleased to present the first data in humans of an IV formulation of clopidogrel at this most prestigious cardiology scientific session," said Dr. Warren D. Cooper, President and CEO of Prism. "PM103 is Prism's second acute care cardiovascular product that is being developed through our accelerated model, which focuses on bringing novel and improved formulations of existing compounds to the market."

About PM103

PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX(R) (clopidogrel bisulfate), an orally available antiplatelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyD
'/>"/>

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
2. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
3. Prism glasses expand the view for patients with hemianopia
4. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
5. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 2014 Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... forward in the federal multidistrict litigation underway in ... Liebhard LLP reports. According to a filing dated ... Stengel has ordered the deposition of a former ... that the witness’s testimony concerning the marketing of ...
(Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
(Date:7/12/2014)... 12, 2014 "The second toes cross over ... painful to wear shoes," said an inventor from East Hartford, ... prevents this from happening. , He then created a prototype ... prevent the second and big toes from overlapping. This avoids ... shoes. Ergonomic and easy to use, it's ideal for people ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of her right ... of his left side. Eating became a difficult task for them ... them enjoy eating again,” said an inventor, from Fayetteville, N.C. As ... PLATE (P C H PLATE). , The PATRICIA CAROL HALL PLATE ... for individuals who suffer from stroke, experience tremors or loss of ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP notes ... metal ion levels to the failure of metal-on-metal hip ... issue of The Journal of Bone & Joint Surgery, ... unilateral Articular Surface Replacement prostheses at least twelve months ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4
... half a million women around the world, including an ... planning methods developed by Georgetown University Medical Centers Institute ... of others use CycleBeads a visual aid developed by ... plan or prevent pregnancy. , Now CycleBeads are ...
... model of Treacher Collins Syndrome (TCS), the Stowers Institutes Trainor ... of craniofacial development either by inactivating a gene implicated in ... The work, which was posted to the Web site of ... teams 2006 discovery of the cellular cause of TCS. ...
... Higher Protein, Fish-based Formula Ideal for Dogs ... The Wellness(R),( http://www.wellnesspetfood.com ) brand of ... the availability of Wellness CORE(TM) Dog Ocean ... CORE Dog line. CORE Ocean delivers a,fish- ...
... Mercury has again been in,the news with the ... sushi by,the New York Times and Oceana/Mercury Policy Project ... 3 pieces of tuna tested had levels,above FDA,s action ... interests,against those covering the news was swift and erroneous. ...
... Company, Inc. (Nasdaq: IPCM ), a leading provider of ... and,Jeffrey Taylor, President and Chief Operating Officer, are scheduled to,present ... Services,Conference in New York, NY., Event: 2008 ... February 11, 2008 Time: 9:00 a.m. ET ...
... it has been common practice to exclude older patients from ... rates. , However, patients such as ... are proving that perhaps age does not always matter. ... that select patients age 65 and older can safely undergo ...
Cached Medicine News:Health News:CycleBeads help women manage their fertility 2Health News:Trainor Lab prevents rare birth defect by inactivating p53 gene 2Health News:Introducing New Wellness(R) CORE(TM) Dog Ocean Formula - The Most Balanced Fish-Based Grain-Free Diet Available 2Health News:Introducing New Wellness(R) CORE(TM) Dog Ocean Formula - The Most Balanced Fish-Based Grain-Free Diet Available 3Health News:Introducing New Wellness(R) CORE(TM) Dog Ocean Formula - The Most Balanced Fish-Based Grain-Free Diet Available 4Health News:Global Consensus on Mercury: Scientists Defend Science Journalists 2Health News:Global Consensus on Mercury: Scientists Defend Science Journalists 3Health News:Global Consensus on Mercury: Scientists Defend Science Journalists 4Health News:IPC The Hospitalist Company, Inc. to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Study finds good outcomes for older lung transplant patients 2
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
All metal for storing 5 cm x 5 cm (2 inches x 2 inches) 35 mm color slides. Each is individually crafted of high grade steel and finished with a durable baked enamel finish....
Individually, self-contained, stackable drawers....
Shandon Wooden Slide File Storage Box...
Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....
Medicine Products: